Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Apogee Therapeutics ( (APGE) ) has issued an update.
On March 23, 2026, Apogee Therapeutics reported positive 52-week maintenance data from Part A of its Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis, showing durable and deepening clinical responses with 3- and 6-month dosing intervals. The biologic achieved high EASI-75 and vIGA 0/1 maintenance rates, substantial itch reduction and increasing EASI 90 and 100 responses over one year, while maintaining a safety profile broadly in line with other IL-13-targeting agents.
The one-year results suggest that zumilokibart could offer a highly differentiated option with as few as two to four injections per year, compared with far more frequent dosing for current standard-of-care biologics. Apogee plans to use these data, along with forthcoming Part B 16-week dose-optimization results expected in the second quarter of 2026, to support initiation of Phase 3 trials in the second half of 2026, positioning the company to pursue a 2029 commercial launch in an atopic dermatitis market it estimates at about $50 billion.
The most recent analyst rating on (APGE) stock is a Hold with a $83.00 price target. To see the full list of analyst forecasts on Apogee Therapeutics stock, see the APGE Stock Forecast page.
Spark’s Take on APGE Stock
According to Spark, TipRanks’ AI Analyst, APGE is a Neutral.
The score is primarily shaped by strong capitalization and low leverage, tempered by substantial and accelerating losses/cash burn typical of a development-stage biotech. Technical signals are mixed/neutral, while valuation is constrained by negative earnings. A notable positive corporate event (encouraging Phase 1b data and a robust upcoming clinical timeline) provides an upside catalyst but does not fully offset financial burn risk.
To see Spark’s full report on APGE stock, click here.
More about Apogee Therapeutics
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing optimized, novel biologic therapies for large inflammatory and immunology markets, including atopic dermatitis, asthma, eosinophilic esophagitis and COPD. Its lead program, zumilokibart (APG777), is a subcutaneous, extended half-life monoclonal antibody targeting IL-13, designed to deliver differentiated efficacy with less frequent dosing and potential best-in-class profiles across multiple indications.
The company’s pipeline targets well-established mechanisms of action while using advanced antibody engineering to enhance half-life and other properties, enabling both monotherapies and combinations aimed at improving durability of response and patient convenience. Apogee is initially prioritizing atopic dermatitis, one of the largest and least penetrated I&I markets, and sees broader “pipeline-in-a-product” potential for zumilokibart in additional inflammatory diseases.
Average Trading Volume: 961,760
Technical Sentiment Signal: Buy
Current Market Cap: $4.59B
For detailed information about APGE stock, go to TipRanks’ Stock Analysis page.